PURPOSE: To determine long-term safety of intravitreal administration of good manufacturing practice (GMP)-grade human bone-marrow-derived CD34(+) cells in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mice with acute retinal ischemia-reperfusion injury, a model for retinal vasculopathy. METHOD: Acute ischemia-reperfusion injury was induced in the right eye of adult NOD-SCID mice (n = 23) by transient elevation of intraocular pressure. Seven days later, 12 injured eyes and 5 normal contralateral eyes were injected each intravitreally with 5 × 10(4) CD34(+) cells isolated under GMP conditions from a healthy human donor bone marrow using an immunomagnetic cell isolation system. The remaining 11 injured eyes were not treated and served as controls. Mice were euthanized 1 day, 4 months, and 8 months later. Both eyes were enucleated and examined by immunohistochemical analysis and hematoxylin and eosin staining. Among mice followed for 8 months, electroretinography (ERG) was performed on both eyes before euthanization. All major organs were examined grossly and histologically after serial sectioning. RESULTS: Immunohistochemical staining 4 months after injection showed detectable CD34(+) cells in the retinal vasculature. ERG at 8 months after CD34(+) cell injection showed signals that were similar in untreated eyes. Histology of the enucleated eyes injected with CD34(+) cells showed no intraocular tumor or abnormal tissue growth after 8 months. Histologic analysis of all major organs showed no abnormal proliferation of human cells. CONCLUSIONS: Intravitreal administration of GMP-grade human bone-marrow-derived CD34(+) cells appears to be well tolerated long-term in eyes with acute retinal ischemic injury. A clinical trial will start to further explore this therapy.
PURPOSE: To determine long-term safety of intravitreal administration of good manufacturing practice (GMP)-grade human bone-marrow-derived CD34(+) cells in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mice with acute retinal ischemia-reperfusion injury, a model for retinal vasculopathy. METHOD: Acute ischemia-reperfusion injury was induced in the right eye of adult NOD-SCIDmice (n = 23) by transient elevation of intraocular pressure. Seven days later, 12 injured eyes and 5 normal contralateral eyes were injected each intravitreally with 5 × 10(4) CD34(+) cells isolated under GMP conditions from a healthy humandonor bone marrow using an immunomagnetic cell isolation system. The remaining 11 injured eyes were not treated and served as controls. Mice were euthanized 1 day, 4 months, and 8 months later. Both eyes were enucleated and examined by immunohistochemical analysis and hematoxylin and eosin staining. Among mice followed for 8 months, electroretinography (ERG) was performed on both eyes before euthanization. All major organs were examined grossly and histologically after serial sectioning. RESULTS: Immunohistochemical staining 4 months after injection showed detectable CD34(+) cells in the retinal vasculature. ERG at 8 months after CD34(+) cell injection showed signals that were similar in untreated eyes. Histology of the enucleated eyes injected with CD34(+) cells showed no intraocular tumor or abnormal tissue growth after 8 months. Histologic analysis of all major organs showed no abnormal proliferation of human cells. CONCLUSIONS: Intravitreal administration of GMP-grade human bone-marrow-derived CD34(+) cells appears to be well tolerated long-term in eyes with acute retinal ischemic injury. A clinical trial will start to further explore this therapy.
Authors: Y Fukuchi; Y Miyakawa; M Kizaki; A Umezawa; K Shimamura; K Kobayashi; T Kuramochi; J Hata; Y Ikeda; N Tamaoki; T Nomura; Y Ueyama; M Ito Journal: Ann Hematol Date: 1999-05 Impact factor: 3.673
Authors: Bodo E Strauer; Michael Brehm; Tobias Zeus; Matthias Köstering; Anna Hernandez; Rüdiger V Sorg; Gesine Kögler; Peter Wernet Journal: Circulation Date: 2002-10-08 Impact factor: 29.690
Authors: Atsushi Otani; Michael Ian Dorrell; Karen Kinder; Stacey K Moreno; Steven Nusinowitz; Eyal Banin; John Heckenlively; Martin Friedlander Journal: J Clin Invest Date: 2004-09 Impact factor: 14.808
Authors: Eric Benoit; Thomas F O'Donnell; Mark D Iafrati; Enrico Asher; Dennis F Bandyk; John W Hallett; Alan B Lumsden; Gregory J Pearl; Sean P Roddy; Krishnaswami Vijayaraghavan; Amit N Patel Journal: J Transl Med Date: 2011-09-27 Impact factor: 5.531
Authors: Susanna S Park; Gerhard Bauer; Mehrdad Abedi; Suzanne Pontow; Athanasios Panorgias; Ravi Jonnal; Robert J Zawadzki; John S Werner; Jan Nolta Journal: Invest Ophthalmol Vis Sci Date: 2014-12-09 Impact factor: 4.799
Authors: Susanna S Park; Elad Moisseiev; Gerhard Bauer; Johnathon D Anderson; Maria B Grant; Azhar Zam; Robert J Zawadzki; John S Werner; Jan A Nolta Journal: Prog Retin Eye Res Date: 2016-10-23 Impact factor: 21.198
Authors: Mandeep S Singh; Susanna S Park; Thomas A Albini; M Valeria Canto-Soler; Henry Klassen; Robert E MacLaren; Masayo Takahashi; Aaron Nagiel; Steven D Schwartz; Kapil Bharti Journal: Prog Retin Eye Res Date: 2019-09-05 Impact factor: 21.198
Authors: Sergio Caballero; Sugata Hazra; Ashay Bhatwadekar; Sergio Li Calzi; Linda J Paradiso; Leonard P Miller; Lung-Ji Chang; Timothy S Kern; Maria B Grant Journal: Invest Ophthalmol Vis Sci Date: 2013-04-26 Impact factor: 4.799
Authors: Rubens C Siqueira; Andre Messias; Katharina Messias; Rafael S Arcieri; Milton A Ruiz; Neiglene F Souza; Lia C Martins; Rodrigo Jorge Journal: Stem Cell Res Ther Date: 2015-03-14 Impact factor: 6.832
Authors: Gangaraju Rajashekhar; Ahmed Ramadan; Chandrika Abburi; Breedge Callaghan; Dmitry O Traktuev; Carmella Evans-Molina; Raj Maturi; Alon Harris; Timothy S Kern; Keith L March Journal: PLoS One Date: 2014-01-09 Impact factor: 3.240
Authors: Conor M Ramsden; Michael B Powner; Amanda-Jayne F Carr; Matthew J K Smart; Lyndon da Cruz; Peter J Coffey Journal: Development Date: 2013-06 Impact factor: 6.868